Эффективность аторвастатина при профилактике инсульта
Аннотация
В статье рассмотрена взаимосвязь риска развития инсульта с различными параметрами липидного обмена. Приведены данные, свидетельствующие о том, что только статины, в отличие от ряда других гиполипидемических препаратов, достоверно снижают риск развития как первого, так и повторного инсульта. Обсуждаются данные исследований, в которых было получено снижение риска развития церебральных событий на фоне применения аторвастатина. Подчеркивается, что при назначении гене-рических препаратов одинаковая степень эффективности и безопасности гарантирована только в случае доказанной терапевтической эквивалентности оригинальному препарату.
Ключевые слова
Об авторах
О. Д. Остроумова
Московский государственный медико-стоматологический университет им. А.И. Евдокимова; Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия
Россия
И. И. Копченов
Московский государственный медико-стоматологический университет им. А.И. Евдокимова
Россия
Россия
Т. Ф. Гусева
Московский государственный медико-стоматологический университет им. А.И. Евдокимова
Россия
Россия
О. В. Бондарец
Московский государственный медико-стоматологический университет им. А.И. Евдокимова
Россия
Россия
Г. Н. Щукина
Московский государственный медико-стоматологический университет им. А.И. Евдокимова
Россия
Россия
Список литературы
1. Смертность населения Российской Федерации, 1998 г. (статистические материалы). М.: Минздрав РФ 2006; 36c.
2. Гусев Е.И., Скворцова В.И., Стаховская Л.В. Проблема инсульта в Российской Федерации: время активных совместных действий. Журнал неврологии и психиатрии, 2007, 8: 4-10.
3. Guidelines for the Primary Prevention of Stroke. A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, Creager MA, Culebras A, Eckel RH, Hart RJ, Hinchey JA, Howard VJ, Jauch EC, Levine SR, Meschia JF, Moore WS, Nixon JV, Pearson TA and on behalf of the American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, Council for High Blood Pressure Research, Council on Peripheral Vascular Disease, and Interdisciplinary Council on Ouali. Stroke, 2011, 42: 517-584.
4. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med., 1989, 320: 904-910.
5. Leppala JM, Virtamo J, Fogelholm R, Albanes D, Heinonen OP. Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. Stroke, 1999, 30: 2535-2540.
6. Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, MacMahon S, Woodward M. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol., 2003, 32: 563-572.
7. Horenstein RB, Smith DE, Mosca L. Cholesterol predicts stroke mortality in the Women's Pooling Project. Stroke, 2002, 33: 1863-1868.
8. Kurth T, Everett BM, Buring JE, Kase CS, Ridker PM, Gaziano JM. Lipid levels and the risk of ischemic stroke in women. Neurology, 2007, 68: 556-562.
9. Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovern PG, Sharrett AR. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke, 2003, 34: 623-631.
10. Bots ML, Elwood PC, Nikitin Y, Salonen JT, Freire de Concalves A, Inzitari D, Sivenius J, Benetou V Tuomilehto J, Koudstaal PJ, Grobbee DE. Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health, 2002, 56(1): 19-24.
11. Sturgeon JD, Folsom AR, Longstreth WT Jr, Shahar E, Rosamond WD, Cushman M. Risk factors for intracerebral hemorrhage in a pooled prospective study. Stroke, 2007, 38: 2718-2725.
12. Suh I, Jee SH, Kim HC, Nam CM, Kim IS, Appel LJ. Low serum cholesterol and haemorrhagic stroke in men: Korea Medical Insurance Corporation Study. Lancet, 2001, 357: 922-925.
13. Sanossian N, Saver JL, Navab M, Ovbiagele B. High-density lipoprotein cholesterol: an emerging target for stroke treatment. Stroke, 2007, 38: 1104-1109.
14. Lindenstrom E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ, 1994, 309: 11-15.
15. Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis, 2008, 196: 489-496.
16. Bowman TS, Sesso HD, Ma J, Kurth T, Kase CS, Stampfer MJ, Gaziano JM. Cholesterol and the risk of ischemic stroke. Stroke, 2003, 34: 2930-2934.
17. Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, Woodward M. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation, 2004, 110: 2678-2686.
18. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general popula-tion.JAMA, 2008, 300: 2142-2152.
19. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA, 2007, 298: 309-316.
20. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke, 2004, 35: 2902-2909.
21. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005, 366: 1267-1278.
22. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol., 2009, 8: 453-463.
23. Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW Palmer MK, O'Leary DH, Grobbee DE, Bots ML. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA, 2007, 297: 1344-1353.
24. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholester-olaemia (ASAP): a prospective, randomised, double-blind trial. Lancet, 2001, 357: 577-581.
25. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation, 2002, 106: 2055-2060.
26. La Rosa J, Grundy SM, Waters DD et al. for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005, 352(14): 1425-34.
27. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial. JAMA, 2001, 285: 1711-8.
28. Kinlay S, Schwartz GG, Olsson AG, et al. High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study. Circulation, 2003, 108: 1560.
29. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National cholesterol educational program goal versus «usual» care in secondary coronary heart disease prevention: The GREek Atorvastatin and Coronary-heart-disease Evaluation Study (GREACE). Cur Med Res Opin, 2002, 18: 220-8.
30. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003, 361: 1149-1158.
31. Guide to Clinical Preventive Services: Report of the U. S. Preventive Services Task Force. Baltimore, MD: Williams and Wilkins; 1996. Available at: http//www.ncbi.nlm.nih.gov/book-shelf/br.fcgi?book_hscps2ed1996&part_A19920. Accessed October 14, 2010.
32. Zhang Y, Galloway JM, Welty TK, Wiebers DO, Whisnant JP, Devereux RB, Kizer JR, Howard BV, Cowan LD, Yeh J, Howard WJ, Wang W, Best L, Lee ET. Incidence and risk factors for stroke in American Indians: the Strong Heart Study. Circulation, 2008, 118: 1577-1584.
33. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil NA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004, 364: 685-96.
34. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care, 2006, 29: 1220-1226.
Для цитирования:
Остроумова О.Д., Копченов И.И., Гусева Т.Ф., Бондарец О.В., Щукина Г.Н. Эффективность аторвастатина при профилактике инсульта. Медицинский Совет. 2015;(12):84-93. https://doi.org/10.21518/2079-701X-2015-12-84-93
For citation:
Ostroumova O.D., Kopchenov I.I., Guseva Т.F., Bondarets O.V., Schukina G.N. The effectiveness of atorvastatin in the prevention of stroke. Meditsinskiy sovet = Medical Council. 2015;(12):84-93. (In Russ.) https://doi.org/10.21518/2079-701X-2015-12-84-93
Просмотров: 77
Послать статью по эл. почте 